Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
Investment is additive to KKR’s existing health care growth strategy
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products
The product is bioequivalent and therapeutically equivalent to the RLD, Vascepa of Amarin
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
National Health Authority (NHA) to host the two-day Arogya Manthan event in New Delhi
Subscribe To Our Newsletter & Stay Updated
